Supplementary Table S3. Safety Population - Grade {greater than or equal to} 3 Adverse Reactions from FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease

Authors :: Richard Pazdur
Ann T. Farrell
Reena Philip
Albert Deisseroth
Rajeshwari Sridhara
Donna Roscoe
Yuan Li Shen
Donna Przepiorka
Aaron Schetter
Qing Xu
Emily Y. Jen
Publication Year :: 2023
Publisher :: American Association for Cancer Research (AACR), 2023.
Abstract: Grade >/= 3 AR

Tools